Enovis is putting a comparatively modest bet ($200 million vs Stryker’s $1.3 billion for Mako) behind the proposition that robotic automation belongs in its surgical future.
Most Popular
Join 13,000+ Subscribers
Get unlimited access to OTW reporting, member discussions, and the weekly newsletter.
